RxDoctor Payments Data

David Mulkey, MD

Family Medicine · Cullman, ALNPI 1396206314

Payments from drug & device makers

$2,370in general payments, 2019–2025

Across 141 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$495
  • Collegium Pharmaceutical, Inc.$360
  • Boston Scientific$194
  • AbbVie$161
  • Forte Bio-pharma LLC$152
  • Novo Nordisk$116
  • plus $893 from 21 others

What the payments were for

  • Food & beverage$2,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,370 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$116,608
Medicare patients
430
Services billed
2,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl1,078$236,175
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen5,325$201,863
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen6,197$159,207
Xtampza ErOxycodone Myristate221$89,312
Buprenorphine190$65,059
Gabapentin4,985$59,131
BelbucaBuprenorphine Hcl52$51,873
Pregabalin2,268$49,235
LinzessLinaclotide88$48,385
ZubsolvBuprenorphine Hcl/Naloxone Hcl57$46,657
ZtlidoLidocaine60$38,831
Naloxone Hcl485$32,829
Hysingla ErHydrocodone Bitartrate68$30,893
ProlateOxycodone Hcl/Acetaminophen11$26,374
Lidocaine190$23,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$360$156,149289 claims
AbbVieLinzess$161$48,38588 claims
Orexo US, Inc.Zubsolv$30$46,65757 claims
Scilex Pharmaceuticals Inc.Ztlido$495$38,83160 claims
Forte Bio-pharma LLCProlate$152$26,37411 claims
Indivior Inc.Suboxone$53$21,50531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →